Simon Barry J. — SEC insider filings
SEC reporting owner CIK 1647994. 24 insider filings on record with FilingPulse; latest filed 2026-10-06.
Transaction summary — filings shown
Covers all 24 filings on record, filed 2020-12-28 to 2026-10-06. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 16 legs across 11 filings — 882,100 shares, $11,966,456 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 34.
- Largest priced transaction: sale of 130,000 shares @ $18.05 ($2,346,604) in ImmunityBio, Inc., filed 2020-12-28.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | Director | 19 | — | 16 legs · 882,100 sh · $11,966,456 | 29 |
| Viracta Therapeutics, Inc. (VIRX) | Director | 4 | — | — | 4 |
| Cue Biopharma, Inc. (CUE) | Director | 1 | — | — | 1 |
Insider filings — Simon Barry J.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-06 | 4 | ImmunityBio, Inc. (IBRX) | Sale (S): 25,000 @ $10.75 | EDGAR |
| 2026-06-26 | 4 | ImmunityBio, Inc. (IBRX) | Sale (S): 25,000 @ $7.88 | EDGAR |
| 2026-06-05 | 4 | ImmunityBio, Inc. (IBRX) | Sale (S): 23,033 @ $7.18 | EDGAR |
| 2026-02-26 | 4 | ImmunityBio, Inc. (IBRX) | Sale (S): 75,000 @ $12.01 | EDGAR |
| 2026-02-24 | 4 | ImmunityBio, Inc. (IBRX) | Sale (S): 10,000 @ $9.25 · Option exercise (M): 15,243 @ $0 · Tax withholding (F): 6,026 @ $8.70 · Sale (S): 165,000 @ $10.25 · Option exercise (M): 15,243 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | ImmunityBio, Inc. (IBRX) | Sale (S): 76,967 @ $6.54 · Sale (S): 75,000 @ $7.88 | EDGAR |
| 2025-02-25 | 4 | ImmunityBio, Inc. (IBRX) | Option exercise (M): 15,243 @ $0 · Tax withholding (F): 5,453 @ $3.42 · Option exercise (M): 15,243 (derivative) @ $0 | EDGAR |
| 2025-01-24 | 4 | ImmunityBio, Inc. (IBRX) | Option exercise (M): 110,020 @ $2.00 · Option exercise (M): 110,020 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Viracta Therapeutics, Inc. (VIRX) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-02-26 | 4 | ImmunityBio, Inc. (IBRX) | Grant/award (A): 45,731 (derivative) @ $0 · Grant/award (A): 159,146 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | ImmunityBio, Inc. (IBRX) | Option exercise (M): 57,200 @ $0 · Tax withholding (F): 22,094 @ $3.36 · Option exercise (M): 57,200 (derivative) @ $0 | EDGAR |
| 2023-09-06 | 4 | ImmunityBio, Inc. (IBRX) | Option exercise (M): 57,199 @ $0 · Option exercise (M): 57,199 (derivative) @ $0 | EDGAR |
| 2023-08-28 | 4 | ImmunityBio, Inc. (IBRX) | Grant/award (A): 114,399 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Viracta Therapeutics, Inc. (VIRX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Viracta Therapeutics, Inc. (VIRX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-03-25 | 4 | ImmunityBio, Inc. (IBRX) | Grant/award (A): 10,714 (derivative) @ $0 | EDGAR |
| 2021-05-25 | 4 | ImmunityBio, Inc. (IBRX) | Sale (S): 14,990 @ $16.09 · Sale (S): 21,223 @ $16.02 · Sale (S): 88,787 @ $16.18 | EDGAR |
| 2021-05-07 | 4 | ImmunityBio, Inc. (IBRX) | Option exercise (M): 56,967 @ $1.75 · Option exercise (M): 56,967 (derivative) @ $0 | EDGAR |
| 2021-03-30 | 4 | Viracta Therapeutics, Inc. (VIRX) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2021-02-08 | 4 | NantKwest, Inc. (NK) | Option exercise (M): 22,100 @ $2.00 · Sale (S): 22,100 @ $23.09 · Option exercise (M): 22,100 (derivative) @ $0 | EDGAR |
| 2021-02-04 | 4 | NantKwest, Inc. (NK) | Option exercise (M): 82,070 @ $2.00 · Sale (S): 82,070 @ $20.65 · Option exercise (M): 82,070 (derivative) @ $0 | EDGAR |
| 2021-01-29 | 4 | NantKwest, Inc. (NK) | Option exercise (M): 36,626 @ $2.00 · Sale (S): 36,626 @ $20.61 · Option exercise (M): 11,304 @ $2.00 · Sale (S): 11,304 @ $20.53 · Option exercise (M): 36,626 (derivative) @ $0 · Option exercise (M): 11,304 (derivative) @ $0 | EDGAR |
| 2021-01-06 | 4 | Cue Biopharma, Inc. (CUE) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2020-12-28 | 4 | NantKwest, Inc. (NK) | Option exercise (M): 130,000 @ $2.00 · Sale (S): 130,000 @ $18.05 · Option exercise (M): 130,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-12-17 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1647994 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs